Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 09, 2023 16:05 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Announces First Quarter 2023 Financial Results

First quarter 2023 total revenues of $153.8 million, compared to $152.5 million in first quarter 2022 Qelbree® net product sales of $25.8 million, compared to $8.3 million in first quarter...
May 02, 2023 16:05 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus to Present at the Bank of America 2023 Health Care Conference

ROCKVILLE, Md., May 02, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
April 25, 2023 16:15 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 9, 2023

ROCKVILLE, Md., April 25, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
April 03, 2023 16:05 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Announces Repayment of Convertible Notes

ROCKVILLE, Md., April 03, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
March 08, 2023 16:05 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus to Participate in Two Upcoming Investor Conferences

ROCKVILLE, Md., March 08, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
March 01, 2023 16:55 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus to Present at the Cowen 43rd Annual Health Care Conference

ROCKVILLE, Md., March 01, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
February 28, 2023 16:05 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Announces Fourth Quarter and Full Year 2022 Financial Results

Full Year 2022 total revenues of $667.2 million, a 15% increase compared to full year 2021Fourth quarter 2022 Qelbree® net product sales of $23.6 million increased 29% compared to third quarter of...
February 14, 2023 16:30 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Enters Into $150 Million Credit Facility

ROCKVILLE, Md., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
February 09, 2023 18:15 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 28, 2023

ROCKVILLE, Md., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
November 22, 2022 17:00 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus to Present at the Piper Sandler 34th Annual Healthcare Conference

ROCKVILLE, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...